BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance ...
JSKN003-005 is a randomized, open-label, controlled, multicenter Phase III clinical study designed to evaluate the efficacy and safety of JSKN003 versus investigator’s choice of regimen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback